Summary & Overview
HCPCS J7503: Tacrolimus Extended-Release (Envarsus XR), Oral, 0.25 mg
HCPCS Level II code J7503 designates the extended-release oral formulation of tacrolimus (Envarsus XR), 0.25 mg. Tacrolimus is a cornerstone immunosuppressant for organ transplant recipients; accurate coding for specific formulations matters for billing, inventory, and utilization tracking nationwide. The code identifies product-level dispensing of the extended-release capsule, distinguishing it from immediate-release formulations and other tacrolimus products.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context and service settings, along with payer coverage considerations, common billing modifiers, and where to expect this code to be used in practice. The publication covers benchmarks and reimbursement context, policy updates that affect coverage and prior authorization, and operational notes relevant to pharmacy and outpatient clinic billing teams.
This summary equips billing managers, pharmacists, and revenue cycle professionals with the primary facts needed to recognize when J7503 applies, the typical sites of service where it is billed, and the payer landscape that most commonly processes claims for this extended-release tacrolimus formulation.
Billing Code Overview
HCPCS Level II code J7503 represents Tacrolimus, extended release (Envarsus XR), oral, 0.25 mg. This code is used to report the administration or dispensing of the extended-release oral formulation of tacrolimus, an immunosuppressive agent commonly prescribed to prevent organ transplant rejection.
Service type: Oral medication, extended-release immunosuppressant
Typical site of service: Outpatient pharmacy dispensing or outpatient clinic administration
Clinical & Coding Specifications
Clinical Context
A 52-year-old kidney transplant recipient presents for routine post-transplant outpatient management. The patient is on maintenance immunosuppression and requires conversion from immediate-release tacrolimus to an extended-release formulation, J7503 (tacrolimus, extended release, Envarsus XR, oral, 0.25 mg), to improve trough-level stability and adherence. The clinical workflow begins with a transplant clinic visit where the transplant nephrologist or advanced practice provider reviews current drug levels, renal function, concomitant medications, and adverse effects. The provider documents rationale for conversion or dose adjustment, prescribes the appropriate milligram strength and dosing schedule, and arranges therapeutic drug monitoring with serial tacrolimus trough levels within 3–7 days after a dose change and periodically thereafter. Pharmacy dispenses the J7503 product and communicates counseling points on administration (consistent timing, avoid grapefruit), adherence, and interactions. Follow-up visits include assessment of renal function, tacrolimus levels, and adverse effects; medication dose is titrated based on therapeutic monitoring and clinical status. Typical sites of service are outpatient transplant clinic, specialty pharmacy dispensing, and occasionally inpatient hospital pharmacy when initiated during a transplant admission.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |